Artera Launches Registry Trial to Measure Real-World Impact and Outcomes of its Prostate Test
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced th [...]
How AI Is Helping Cancer Patients: Saving Lives And Money
Cancer treatment is costly. The average cost of cancer care in the U.S. is around $150,000 per patient—more than four times t [...]
The ArteraAI Prostate Test Enhanced with New Insights for Higher Risk Patients with Localized Prostate Cancer
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated [...]
Artera Presenting Validation Data at 2025 ASCO Annual Meeting Highlighting How Multimodal AI Platform (MMAI) is Advancing Personalized Cancer Care
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announ [...]
TIME100 Health: Andre Esteva
Andre Esteva is pioneering a future where AI can personalize therapies to improve health. “Doctors are the first to tell you [...]
Precision Medicine for Prostate Cancer — AI can help patients decide whether active surveillance is right for them
The multimodal ArteraAI Prostate Testopens in a new tab or window (AI Test) is currently the only test that provides insights [...]
Diagnexia and Artera Partner to Bring Groundbreaking AI Prostate Test to the UK
Diagnexia, the UK’s leading provider of AI-powered digital pathology diagnostic services, is thrilled to announce an exclusiv [...]
The 4 step process to achieve AI data locality while serving AI globally
As part of Artera’s mission to improve patient outcomes globally, Artera launched a highly successful product for patients wi [...]
Phase 3 trial launches of ArteraAI Prostate test for treatment selection
The first patient has been enrolled in the phase 3 PROSTATE-IQ trial (NCT06274047), assessing the ability of the ArteraAI Pro [...]